OCTANe Capital Series: Meet RCT Bioventures

OCTANe's Meet the VC series brings entrepreneurs and VCs together.

Join us as we meet Paul Grand from RCT BioVentures. Research Corporation Technologies (RCT) has a very unique business model and is actively investing in startup biomedical companies. 

This program is for entrepreneurs and inventors only.

Paul Grand
Managing Director, Pacific Coast Office

Paul Grand represents RCT and the RCT BioVentures early-stage investment program to start-up companies, research institutions, and entrepreneurs on the west coast of the United States. His focus is on medical device investments. Paul has built, operated, recruited management and raised financing for eight high technology, medical device and biotechnology companies. He led RCT’s investment in VasoNova Inc. and served as a manager of RCT's investment in Coronis Medical Ventures. Paul is interested in meeting with early-stage medical device companies seeking start-up financing, medical device entrepreneurs, and inventors.

About RCT BioVentures:

The RCT BioVentures program is the vehicle through which Research Corporation Technologies invests in start-up or early-stage companies with technologies that promise patented biomedical products with a clear competitive advantage.

RCT has assets of more than $300 million to advance technology development through flexible, long-term investment options. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.